Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | CASP9 |
| Gene Name: | CASP9 |
| Protein Full Name: | Caspase-9 |
| Alias: | APAF-3; Apoptotic protease activating factor 3; Apoptotic protease Mch-6; CASP-9; Caspase 9, apoptosis-related cysteine peptidase; Caspase9; Caspase-9; ICE-LAP6; ICE-like apoptotic protease 6; MCH6; RNCASP9 |
| Mass (Da): | 46281 |
| Number AA: | 416 |
| UniProt ID: | P55211 |
| Locus ID: | 842 |
| COSMIC ID: | CASP9 |
| Gene location on chromosome: | 1p36.2 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 20238 |
| Percent of cancer specimens with mutations: | 0.34 |
| Normal role description: | CASP9 is an aspartic acid protease involved in the pro-apoptotic caspase cascade responsible for programmed cell death. Activation of CASP9 occurs through cleavage by caspase APAF1. CASP9 is ubiquitously expressed with the highest levels of expression in the heart. Mutations in the promoter region of the CASP9 locus is associated with increased risk of lung, colon and gastric cancers. Decreased activity of CASP9 results in inhibition of apoptosis a increased longevity of cancer cells. |